While GLP-1 and next-generation obesity therapies have become widely recognized for their role in weight management, the Company believes maintaining lean muscle mass during obesity-related weight loss may become an increasingly important area of product development and clinical focus
A percentage of people will not be able to tolerate the new pharmacotherapies or achieve the individualised goals and others may not have long-term access to these treatments
So, typically the more effective the medication, the more likely the risk of adverse events
Keep an eye on the retatrutide availability timeline for updates on these newer agents
Phase 2 NEJM titration (still common in research) Phase 2 retatrutide titration schedule Phase Initiation Weeks Weeks 1-4 Weekly Dose 1 mg Phase Early escalation Weeks Weeks 5-8 Weekly Dose 2 mg Phase Mid escalation Weeks Weeks 9-12 Weekly Dose 4 mg Phase High escalation Weeks Weeks 13-16 Weekly Dose 8 mg Phase Maximum Weeks Weeks 17+ Weekly Dose 12 mg Source: Jastreboff et al., NEJM 2023
Rather, the labels downplay the severity of gastroparesis symptoms, and omit that they can be a feature of potentially life-threatening digestive impairment. Plaintiffs also noted that defendants failed to warn users that they need to stay on the drugs for the rest of their lives, or else they are likely to gain the weight back